US challenges 'bogus' patents on Ozempic and other drugs in effort to spur competition
Time:2024-05-22 02:36:23 Source:worldViews(143)
WASHINGTON (AP) — Federal regulators are challenging patents on 20 brand name drugs, including the blockbuster weight-loss injection Ozempic, in the latest action by the Biden administration targeting industry practices that drive up pharmaceutical prices.
The Federal Trade Commission on Tuesday sent warning letters to 10 drugmakers, taking issue with patents on popular drugs for weight loss, diabetes, asthma and other reparatory conditions. The letters allege that certain patents filed by Novo Nordisk, GlaxoSmithKline, AstraZeneca and seven other companies are inaccurate or misleading.
Brand-name drugmakers use patents to protect their medicines and stave off cheaper, generic medicines. Most blockbuster drugs are protected by dozens of patents covering various ingredients, manufacturing processes and intellectual property. Generic drugmakers can only launch their own cheaper versions if the patents have expired or are successfully challenged in court.
Previous:The Latest
Next:JoJo Siwa goes wild: Karma singer accused of getting drunk at Disney World after turning 21
You may also like
- Trump film shocks Cannes as former US President is depicted 'raping' his then
- Legendary rugby league star Wally Lewis appeals for concussion and CTE awareness support
- People enjoy outdoor activities as spring flowers bloom across China
- GOP lawsuits over voting creates shadow war ahead of the election
- Why US Catholics are planning pilgrimages in communities across the nation
- Israel's Netanyahu says to increase pressure on Hamas
- David Beckham gushes over his wife Victoria's age
- Sydney Sweeney 'apologizes' for 'having great t**s' during bikini
- Siblings trying to make US water polo teams for Paris Olympics